At ATTD 2026, Dexcom (Nasdaq:DXCM) outlined a range of ways in which its continuous glucose monitors (CGMs) benefit people with diabetes.

Dexcom will present the full data from several studies at the Advanced Technologies and Treatments for Diabetes conference, ...

DexCom DXCM recently announced that it has received FDA clearance for its CGM-integrated basal insulin dosing optimizer, Dexcom Smart Basal, for use by adults with Type 2 diabetes on glargine U-100 ...

Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.

Diabetes Care Devices Market Insights, Competitive Landscape, and Market Forecast - 2034” report provides the current ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...

Continuous glucose monitor maker Dexcom announced that it will partner with insulin pump maker Silicon Valley-based Asante Solutions so that users of Asante devices will be able to access that data ...

Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...

Enhanced Smart Food Logging experience now provides nutritional breakdown of meals Advanced AI-enabled features will deliver easy meal tracking to transform daily metabolic health management ...

Analysts feared the advent of GLP-1 medications would harm DexCom's blood glucose monitoring devices. However, as its turns out, DexCom's devices are being prescribed together with GLP-1s. The company ...